Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations


22.61   0.05 (0.22%) 11-25 13:00
Open: 22.56 Pre. Close: 22.56
High: 23.23 Low: 22.47
Volume: 112,058 Market Cap: 979(M)

Technical analysis

as of: 2022-11-25 2:00:00 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 27.24     One year: 29.78
Support: Support1: 19.81    Support2: 16.49
Resistance: Resistance1: 23.33    Resistance2: 25.5
Pivot: 21.68
Moving Average: MA(5): 22.19     MA(20): 22.14
MA(100): 26.94     MA(250): 27.07
MACD: MACD(12,26): -0.3     Signal(9): -0.5
Stochastic oscillator: %K(14,3): 62.8     %D(3): 49.9
RSI: RSI(14): 51.3
52-week: High: 36.34  Low: 18.69
Average Vol(K): 3-Month: 356 (K)  10-Days: 279 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ RGNX ] has closed below upper band by 18.1%. Bollinger Bands are 48.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 22.79 - 22.87 22.87 - 22.94
Low: 21.86 - 21.97 21.97 - 22.05
Close: 22.4 - 22.56 22.56 - 22.7

Company Description

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.

Headline News

Wed, 23 Nov 2022
REGENXBIO Inc. (NASDAQ:RGNX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Tue, 22 Nov 2022
Looking Into Regenxbio's Return On Capital Employed - Regenxbio (NASDAQ:RGNX) - Benzinga

Tue, 22 Nov 2022
REGENXBIO to Participate in Upcoming Investor Conferences - Regenxbio (NASDAQ:RGNX) - Benzinga

Mon, 21 Nov 2022
Morgan Stanley Adjusts Price Target on REGENXBIO to $50 From $52, Maintains Overweight Rating -

Tue, 08 Nov 2022
TheStreet Lowers REGENXBIO (NASDAQ:RGNX) to D+ - MarketBeat

Thu, 03 Nov 2022
Why Regenxbio (RGNX) Shares Are Falling Today - Regenxbio (NASDAQ:RGNX) - Benzinga

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 43 (M)
Shares Float 39 (M)
% Held by Insiders 7.6 (%)
% Held by Institutions 88.2 (%)
Shares Short 2,670 (K)
Shares Short P.Month 2,920 (K)

Stock Financials

EPS 1.67
EPS Est Next Qtl -0.77
EPS Est This Year -2.94
EPS Est Next Year -2.96
Book Value (p.s.) 13.02
Profit Margin (%) 15.3
Operating Margin (%) 24.5
Return on Assets (ttm) 8.7
Return on Equity (ttm) 14.3
Qtrly Rev. Growth -13.9
Gross Profit (p.s.) 5.47
Sales Per Share 11.08
EBITDA (p.s.) 2.98
Qtrly Earnings Growth 0
Operating Cash Flow 173 (M)
Levered Free Cash Flow 100 (M)

Stock Valuations

PE Ratio 13.45
PEG Ratio -1.8
Price to Book value 1.73
Price to Sales 2.03
Price to Cash Flow 5.64

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.